Table of Contents
- Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
- Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
- Chapter 3. Atherosclerotic Cardiovascular Disease Market: By Disease Type Segment Market Trends, Size, and Future Outlook
- By Disease Type Segment Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Disease Type Definitions, Technology Landscape
- By Disease Type Segment Market Drivers
- Product Launches
- Technology Launches
- Rising prevalence of coronary artery disease globally
- By Disease Type Segment Market Restraints
- Limitations of current treatment approaches for complex lesions
- Chapter 4. Atherosclerotic Cardiovascular Disease Market: By Therapeutics Segment Market Trends, Size, and Future Outlook
- By Therapeutics Segment Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Therapeutics Definitions, Technology Landscape
- By Therapeutics Segment Market Drivers
- Strong pipeline of novel small molecules and biologics
- Approvals of targeted therapies like PCSK9 inhibitors
- By Therapeutics Segment Market Restraints
- Failure of many candidates in late-stage clinical trials
- Premium pricing of novel therapies
- Chapter 5. Atherosclerotic Cardiovascular Disease Market: By Distribution Channel Segment Market Trends, Size, and Future Outlook
- By Distribution Channel Segment Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Distribution Channel Definitions, Technology Landscape
- By Distribution Channel Segment Market Drivers
- Rising number of ASCVD diagnostic procedures and surgeries
- By Distribution Channel Segment Market Restraints
- Budget constraints in hospitals and clinics
- Chapter 6. Atherosclerotic Cardiovascular Disease Market: Regional Market Trends, Size, and Future Outlook
- North America
- North America Region Market Size (US$), CAGR (%), and Forecast (2022-2030)
- North America Definitions, Technology Landscape
- North America Market Drivers
- High prevalence of obesity and hypertension
- Favorable reimbursement policies
- North America Market Restraints
- Stringent regulatory policies in the U.S.
- Country Outlook
- U.S.
- Canada
- Europe
- Europe Region Market Size (US$), CAGR (%), and Forecast (2022-2030)
- Europe Definitions, Technology Landscape
- Europe Market Drivers
- Rising geriatric population
- Increasing healthcare expenditure
- Europe Market Restraints
- Pricing pressure in European countries
- Country Outlook
- UK
- Germany
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Asia Pacific Region Market Size (US$), CAGR (%), and Forecast (2022-2030)
- Asia Pacific Definitions, Technology Landscape
- Asia Pacific Market Drivers
- Growing medical tourism for cardiovascular procedures
- Improving healthcare infrastructure
- Asia Pacific Market Restraints
- Limited patient awareness in low-income countries
- Country Outlook
- China
- Japan
- India
- South Korea
- Australia
- ASEAN
- Rest of APAC
- Latin America
- Latin America Region Market Size (US$), CAGR (%), and Forecast (2022-2030)
- Latin America Definitions, Technology Landscape
- Latin America Market Drivers
- Latin America Market Restraints
- Country Outlook
- Brazil
- Argentina
- Colombia
- Rest of LATAM
- Middle East & Africa
- Middle East & Africa Region Market Size (US$), CAGR (%), and Forecast (2022-2030)
- Middle East & Africa Definitions, Technology Landscape
- Middle East & Africa Market Drivers
- Middle East & Africa Market Restraints
- Country Outlook
- Nigeria
- Saudi Arabia
- GCC
- Rest of the Countries
- North America
- Chapter 7. Atherosclerotic Cardiovascular Disease Market: Competitive Landscape
- Amgen
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- AstraZeneca
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Bayer
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Johnson & Johnson
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Merck
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Novartis
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Pfizer
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Sanofi
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Abbott Laboratories
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Teva Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Amgen
- Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
- Appendix
- About Us
Frequently Asked Questions
The current market size of the Atherosclerotic Cardiovascular Disease industry is USD 150.8 billion in 2023.
Rising prevalence of obesity, hypertension, diabetes, growing geriatric population, sedentary lifestyles, changing treatment patterns.
High cost of therapies, side effects of statins, failure of clinical trials, stringent regulatory policies, limited awareness in developing regions.
The coronary artery disease segment leads the Atherosclerotic Cardiovascular Disease Market owing to its high prevalence and increasing incidence globally.
Amgen, AstraZeneca, Bayer, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi, Abbott Laboratories, Teva Pharmaceuticals.
The market is expected to grow at a CAGR of 3.8% from USD 150.8 billion in 2023 to USD 195.8 billion in 2030.
Increasing prevalence of risk factors like obesity, diabetes, hypertension, growing geriatric population, sedentary lifestyles, rising healthcare expenditure, and technologically advanced treatment options.